Our team ensures a seamless experience with: Personalized Care : Tailored plans to match your unique health goals
The Blue Cross Blue Shield Federal Employee Program criteria for Saxenda and Wegovy, policy 5.99.030, effective July 1, 2026, require prior participation in a comprehensive weight management program, and at renewal that an adult has lost at least 5 percent of baseline body weight OR the patient has continued to maintain their initial 5 percent weight loss. That is one of the few places in these documents where maintaining rather than losing is written down as a reason to keep paying
Further, if documentation states uncontrolled, did the clinician specify hyperglycemia or hypoglycemia
According to the FDA, Wegovy is indicated for chronic weight management in patients with a body mass index (BMI) of 27 kg/m2 or greater who have at least one weight-related ailment or in patients with a BMI of 30 kg/m2 or greater
Daily injections can feel burdensome, especially when results are modest